News | Cath Lab | November 21, 2016

Study Finds STEMI Post-conditioning is Not as Beneficial as Previously Believed

November 21, 2016 – A single-center study sponsored by the National Institutes of Health (NHLBI) failed to show an early benefit of postconditioning (the application of brief periods of ischemia during the initial phase of reperfusion) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous intervention (PCI) and stenting. The study was conducted by researchers at the Minneapolis Heart Institute Foundation after their findings in a previously published small, nonrandomized study demonstrated that patients who underwent postconditioning had improved left ventricular (LV) function following their myocardial infarction.

Principal investigator Jay Traverse, M.D. developed the study to try and improve upon several previous trials from Europe and Asia that found postconditioning had mixed results in the setting of STEMI cases. “We sought to study the most optimal patient population with STEMI that could benefit from postconditioning to see if it is really effective,” Traverse said. “To accomplish that, we only enrolled patients with a totally occluded major coronary artery on presentation without evidence of collateral blood flow, with limited ishemic times between one and six hours and no evidence of pre-infarction angina, a powerful mitigator of infarct size. We also performed the postconditioning intervention immediately upon reperfusion with a guidewire, because the benefits of postconditioning in animals is lost if postconditioning is delayed for even one minute following reperfusion.”

The MRI-based study randomized 165 patients to postconditioning followed by PCI and stenting versus routine primary PCI and stenting. The postconditioning intervention consisted of four 30-second balloon inflations separated by 30 seconds of reperfusion. A total of 101 patients met final enrollment criteria and underwent MRI measurements of infarct size and myocardial salvage one to three days following PCI.

“Unfortunately, we found that the addition of postconditioning to primary PCI had no effect on infarct size and myocardial salvage. In the postconditioning group (n=53), mean infarct size was 21.1 g vs 20.4 g in the control group (n=48) and the myocardial salvage index was 16.8 in the postconditioning group and 15.9 in the control group. No benefit of postconditioning was observed when the data was stratified by ischemic times, sex or age,” Traverse said.
He is not entirely ready to abandon post-conditioning, although it is possible that the reperfusion injury described in animal models may not occur in humans. The research team is analyzing follow-up MRIs from these patients taken at three months and one year. “It is possible that we may see a delayed benefit of postconditioning on LV function since previous studies have not examined this later time point,” he explained.

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init